Stock Track | Bionano Genomics Plummets Over 5% on Disappointing Q4 2024 Revenue Outlook and Full Year Decline

Stock Track01-13

Bionano Genomics (BNGO) stock plummeted over 5% in the pre-market session on Monday, following the company's release of preliminary unaudited financial results for the fourth quarter and full year 2024.

The key highlights from the preliminary results that likely contributed to the stock's decline are:

Preliminary Q4 2024 revenue is expected to be between $7.9 million and $8.1 million, representing an estimated 25% decrease compared to Q4 2023. This is primarily due to the discontinuation of certain clinical service products in 2024.
For the full year 2024, revenue is expected to be in the range of $30.5 million to $30.7 million, an estimated 15% decrease from $36.1 million in revenue for 2023.

Despite the revenue decline, Bionano reported some positive developments in its core business:

The installed base of its optical genome mapping (OGM) systems reached an estimated 371 as of year-end 2024, a 14% increase over 2023.
The company achieved several milestones, including the commercial release of its high-throughput Stratys system, advancements in its VIA software for data analysis, and the establishment of a Category I CPT code for OGM by the American Medical Association.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1141499582?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-01-13 22:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141499582","market":"hk","top_or_hot":-1,"title":"Stock Track | Bionano Genomics Plummets Over 5% on Disappointing Q4 2024 Revenue Outlook and Full Year Decline","media":"Stock Track","content":"<p>Bionano Genomics (BNGO) stock plummeted over 5% in the pre-market session on Monday, following the company's release of preliminary unaudited financial results for the fourth quarter and full year 2024.</p>\n\n<p>The key highlights from the preliminary results that likely contributed to the stock's decline are:\n<ul>\n<li>Preliminary Q4 2024 revenue is expected to be between $7.9 million and $8.1 million, representing an estimated 25% decrease compared to Q4 2023. This is primarily due to the discontinuation of certain clinical service products in 2024.</li>\n<li>For the full year 2024, revenue is expected to be in the range of $30.5 million to $30.7 million, an estimated 15% decrease from $36.1 million in revenue for 2023.</li>\n</ul>\n</p>\n\n<p>Despite the revenue decline, Bionano reported some positive developments in its core business:\n<ul>\n<li>The installed base of its optical genome mapping (OGM) systems reached an estimated 371 as of year-end 2024, a 14% increase over 2023.</li>\n<li>The company achieved several milestones, including the commercial release of its high-throughput Stratys system, advancements in its VIA software for data analysis, and the establishment of a Category I CPT code for OGM by the American Medical Association.</li>\n</ul>\n</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Bionano Genomics Plummets Over 5% on Disappointing Q4 2024 Revenue Outlook and Full Year Decline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Bionano Genomics Plummets Over 5% on Disappointing Q4 2024 Revenue Outlook and Full Year Decline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-01-13 22:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Bionano Genomics (BNGO) stock plummeted over 5% in the pre-market session on Monday, following the company's release of preliminary unaudited financial results for the fourth quarter and full year 2024.</p>\n\n<p>The key highlights from the preliminary results that likely contributed to the stock's decline are:\n<ul>\n<li>Preliminary Q4 2024 revenue is expected to be between $7.9 million and $8.1 million, representing an estimated 25% decrease compared to Q4 2023. This is primarily due to the discontinuation of certain clinical service products in 2024.</li>\n<li>For the full year 2024, revenue is expected to be in the range of $30.5 million to $30.7 million, an estimated 15% decrease from $36.1 million in revenue for 2023.</li>\n</ul>\n</p>\n\n<p>Despite the revenue decline, Bionano reported some positive developments in its core business:\n<ul>\n<li>The installed base of its optical genome mapping (OGM) systems reached an estimated 371 as of year-end 2024, a 14% increase over 2023.</li>\n<li>The company achieved several milestones, including the commercial release of its high-throughput Stratys system, advancements in its VIA software for data analysis, and the establishment of a Category I CPT code for OGM by the American Medical Association.</li>\n</ul>\n</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNGO","symbol_name":"Bionano Genomics","start_time":0,"source_url":"","article_id":"1141499582","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141499582","pubTimestamp":1736779164,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Bionano Genomics  stock plummeted over 5% in the pre-market session on Monday, following the company's release of preliminary unaudited financial results for the fourth quarter and full year 2024.The key highlights from the preliminary results that likely contributed to the stock's decline are:. Preliminary Q4 2024 revenue is expected to be between $7.9 million and $8.1 million, representing an estimated 25% decrease compared to Q4 2023. This is primarily due to the discontinuation of certain cl","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNGO":"Bionano Genomics"},"translate_title":"股票赛道Bionano Genomics因2024年第四季度收入前景令人失望和全年下滑而暴跌超过5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNGO":1},"content_text":"Bionano Genomics (BNGO) stock plummeted over 5% in the pre-market session on Monday, following the company's release of preliminary unaudited financial results for the fourth quarter and full year 2024.\nThe key highlights from the preliminary results that likely contributed to the stock's decline are:\n\nPreliminary Q4 2024 revenue is expected to be between $7.9 million and $8.1 million, representing an estimated 25% decrease compared to Q4 2023. This is primarily due to the discontinuation of certain clinical service products in 2024.\nFor the full year 2024, revenue is expected to be in the range of $30.5 million to $30.7 million, an estimated 15% decrease from $36.1 million in revenue for 2023.\n\nDespite the revenue decline, Bionano reported some positive developments in its core business:\n\nThe installed base of its optical genome mapping (OGM) systems reached an estimated 371 as of year-end 2024, a 14% increase over 2023.\nThe company achieved several milestones, including the commercial release of its high-throughput Stratys system, advancements in its VIA software for data analysis, and the establishment of a Category I CPT code for OGM by the American Medical Association.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1141499582"}